Drug Profile
SCH 486757
Alternative Names: SCH-486757Latest Information Update: 12 Jun 2013
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antitussives
- Mechanism of Action Nociceptin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cough
Most Recent Events
- 01 Jan 2013 Discontinued - Phase-II for Cough in United Kingdom (PO)
- 04 Nov 2009 Schering-Plough has been acquired and merged into Merck & Co
- 30 Nov 2007 Schering-Plough initiates enrolment in a phase II trial for Cough in the UK (NCT00506987)